Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN421 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Q2W | EXPERIMENTAL | REGN421 (SAR153192) taken once every two weeks (Q2W) |
| Name | Type | Description |
|---|---|---|
| REGN421(SAR153192) | DRUG | - |
Inclusion Criteria: 1. Male or female 18 years of age or older 2. Histologically diagnosis of advanced solid malignancy, with no standard therapeutic options of proven benefit. 3. Patients with measurable or non-measurable disease 4. At least 6 weeks must have elapsed since the last dose of bevaciz...
REGN421 is an investigational small molecule being studied for the treatment of advanced solid malignancies. It is in Phase 1 clinical development and has been evaluated in a completed trial involving patients with advanced solid tumors.
REGN421 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol REGN. The drug is currently in Phase 1 clinical development for advanced solid malignancies.
REGN421 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 trial of REGN421 in advanced solid malignancies has been completed.
REGN421 has been studied in one clinical trial, NCT00871559, titled 'A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies.' This Phase 1 trial was completed and enrolled 83 participants in the United States.
Yes, REGN421 is also known as SAR153192. The clinical trial NCT00871559 refers to the drug as REGN421(SAR153192), indicating that both names are used for the same investigational agent being developed for advanced solid malignancies.